NCT01211964

LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects

LEO 22811 - A Single Dose Bioavailability Study of Oral Solid Dosage Form Versus Oral Solution Including Fed Versus Fasted State in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this phase 1 study is to determine the relative bioavailability and pharmacokinetics following single oral dose administration of LEO 22811 solution compared to LEO 22811 tablet in healthy male subjects as well as to determine the effect of food on the single oral dose pharmacokinetics of LEO 22811 tablet in healthy male subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LEO 22811	Oral administration of solution and tablet.

Timeline

• Start date: 2010-09-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2010-09-30
• Last updated: 2025-02-24

Locations

1 site across 1 country: United Kingdom